Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
SARS-CoV-2
antibody escape
bamlanivimab
deep mutational scanning
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
20 04 2021
20 04 2021
Historique:
received:
22
02
2021
revised:
22
03
2021
accepted:
26
03
2021
pubmed:
13
4
2021
medline:
13
4
2021
entrez:
12
4
2021
Statut:
ppublish
Résumé
Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can render monoclonal antibodies ineffective. Here, we completely map all of the mutations to the SARS-CoV-2 spike receptor-binding domain (RBD) that escape binding by a leading monoclonal antibody, LY-CoV555, and its cocktail combination with LY-CoV016. Individual mutations that escape binding by each antibody are combined in the circulating B.1.351 and P.1 SARS-CoV-2 lineages (E484K escapes LY-CoV555, K417N/T escapes LY-CoV016). In addition, the L452R mutation in the B.1.429 lineage escapes LY-CoV555. Furthermore, we identify single amino acid changes that escape the combined LY-CoV555+LY-CoV016 cocktail. We suggest that future efforts diversify the epitopes targeted by antibodies and antibody cocktails to make them more resilient to the antigenic evolution of SARS-CoV-2.
Identifiants
pubmed: 33842902
doi: 10.1016/j.xcrm.2021.100255
pii: S2666-3791(21)00071-9
pmc: PMC8020059
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100255Subventions
Organisme : NIAID NIH HHS
ID : R01 AI127893
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI140891
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI141707
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Elife. 2021 Jan 19;10:
pubmed: 33463525
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
PLoS Pathog. 2021 Apr 8;17(4):e1009453
pubmed: 33831132
Cell. 2020 Aug 6;182(3):744-753.e4
pubmed: 32553273
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):
pubmed: 34417349
J Virol. 2020 Sep 29;94(20):
pubmed: 32699095
J Open Source Softw. 2020;5(52):
pubmed: 34189395
Science. 2020 Nov 20;370(6519):950-957
pubmed: 32972994
Appl Environ Microbiol. 2007 Feb;73(4):1189-98
pubmed: 17189442
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Nat Microbiol. 2021 Oct;6(10):1233-1244
pubmed: 34548634
Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7550-E7558
pubmed: 30037990
Elife. 2020 Oct 28;9:
pubmed: 33112236
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
JAMA. 2021 Apr 6;325(13):1324-1326
pubmed: 33571356
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
Elife. 2021 Feb 08;10:
pubmed: 33554856
Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4
pubmed: 33535027
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Nature. 2021 May;593(7857):130-135
pubmed: 33684923